The Antitumor Assessment Core Facility was established in 2003 to provide expert support for early discovery of effective antitumor agents and therapeutics. The Core provides resources, professional and technical expertise and advisory services related to the evaluation of agents with potential therapeutic activity, and works closely with investigators to establish in vivo mouse models for the design and execution of pharmacokinetic, toxicity and In vivo efficacy studies. As such, the Core provides a major vehicle to facilitate pre-clinical studies and is a major contributor to the translational mission of the Center. The Core also determines the best formulation, administration route, and treatment schedule for each new compound, either alone or in combination with other agents. The Core helps investigators to design and plan their experiments, prepare animal protocols and grant applications involving animal studies, and analyzes and summarizes data for publication. Importantly, the Core acts as a central coordinator for studies involving support from several core facilities (including Animal Imaging, Comparative Pathology, Tissue Procurement Service, Analytical Pharmacology, Organic Synthesis, Microarray, Radiation Facility, and Cytology) so that studies are carried out properly and in a time- and cost-efficient manner. The services and collaborative work provided by the Antitumor Assessment Core has supported the research of 56 investigators from 9 programs. A particularly exciting example of the work supported is: in 2010 the Core provided support services that were used by Dr. Charles Sawyer's group (ET and CBEP Programs) to develop ARN-509, an Androgen Receptor (AR) inhibitor targeting castration-resistant prostate cancer (CRPC), the most advanced form of this disease. This study has led to a Phase l/ll Clinical Trial currently ongoing at MSKCC. The Core undertook all the animal studies performed at MSKCC for this work.
The Antitumor Assessment Core Facility provides support for the evaluation of effective antitumor agents and therapeutics and thereby directly advances the translational research activities of Memorial Sloan- Kettering Cancer Center.
|Steuer, Conor E; Behera, Madhusmita; Berry, Lynne et al. (2016) Role of race in oncogenic driver prevalence and outcomes in lung adenocarcinoma: Results from the Lung Cancer Mutation Consortium. Cancer 122:766-72|
|Dominguez-Rosado, Ismael; Moutinho Jr, Vitor; DeMatteo, Ronald P et al. (2016) Outcomes of the Memorial Sloan Kettering Cancer Center International General Surgical Oncology Fellowship. J Am Coll Surg 222:961-6|
|Iasonos, Alexia; O'Quigley, John (2016) Integrating the escalation and dose expansion studies into a unified Phase I clinical trial. Contemp Clin Trials 50:124-34|
|Ulaner, Gary A; Hyman, David M; Ross, Dara S et al. (2016) Detection of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer Using 89Zr-Trastuzumab PET/CT. J Nucl Med 57:1523-1528|
|Brown, Anna M; Nagala, Sidhartha; McLean, Mary A et al. (2016) Multi-institutional validation of a novel textural analysis tool for preoperative stratification of suspected thyroid tumors on diffusion-weighted MRI. Magn Reson Med 75:1708-16|
|Akkari, Leila; Gocheva, Vasilena; Quick, Marsha L et al. (2016) Combined deletion of cathepsin protease family members reveals compensatory mechanisms in cancer. Genes Dev 30:220-32|
|Theilen, Till M; Chou, Alexander J; Klimstra, David S et al. (2016) Esophageal Adenocarcinoma and Squamous Cell Carcinoma in Children and Adolescents: Report of 3 Cases and Comprehensive Literature Review. J Pediatr Surg Case Rep 5:23-29|
|Robinson, June K; Halpern, Allan C (2016) Cost-effective Melanoma Screening. JAMA Dermatol 152:19-21|
|Calzavara-Pinton, Pier Giacomo; Rossi, Maria Teresa; Zanca, Arianna et al. (2016) Oral Polypodium leucomotos increases the anti-inflammatory and melanogenic responses of the skin to different modalities of sun exposures: a pilot study. Photodermatol Photoimmunol Photomed 32:22-7|
|Ripley, R Taylor; Suzuki, Kei; Tan, Kay See et al. (2016) Postinduction positron emission tomography assessment of N2 nodes is not associated with ypN2 disease or overall survival in stage IIIA non-small cell lung cancer. J Thorac Cardiovasc Surg 151:969-77, 979.e1-3|
Showing the most recent 10 out of 4768 publications